Skip to content
Elzonris(tagraxofusp)
Elzonris (tagraxofusp) is a protein pharmaceutical. Tagraxofusp was first approved as Elzonris on 2018-12-21. It is used to treat malignant histiocytic disorders in the USA. It has been approved in Europe to treat lymphoma.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Elzonris
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tagraxofusp
Tradename
Proper name
Company
Number
Date
Products
Elzonristagraxofusp-erzsStemline TherapeuticsN-761116 RX2018-12-21
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
elzonrisBiologic Licensing Application2020-06-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
malignant histiocytic disordersD015620
Agency Specific
FDA
EMA
Expiration
Code
tagraxofusp, Elzonris, Stemline Therapeutics, Inc.
2025-12-21Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XX: Other antineoplastic agents in atc
L01XX67: Tagraxofusp
HCPCS
Code
Description
J9269
Injection, tagraxofusp-erzs, 10 micrograms
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0648
Myelomonocytic leukemia chronicD015477C93.1223
Myelodysplastic syndromesD009190D46212
Primary myelofibrosisD055728D47.4112
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0212
Multiple myelomaD009101C90.0111
LeukemiaD007938C95111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic neoplasmsD01933711
T-cell lymphomaD01639911
Hodgkin diseaseD006689C8111
B-cell lymphomaD01639311
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAGRAXOFUSP
INNtagraxofusp
Description
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Classification
Protein
Drug classfusion proteins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID2055491-00-2
RxCUI
ChEMBL IDCHEMBL4297573
ChEBI ID
PubChem CID
DrugBankDB14731
UNII ID8ZHS5657EH (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 264 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elzonris
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
113 adverse events reported
View more details